Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2006
05/02/2006US7037647 Prostate-specific membrane antigen and uses thereof
05/02/2006US7037534 Inactivation of viral infections agents by chemiluminescence activated light-sensitive compounds
05/02/2006US7037524 Oral delivery of a botanical
05/02/2006US7037499 Adjuvant for transcutaneous immunization
05/02/2006US7037498 Antibodies to insulin-like growth factor I receptor
05/02/2006US7037495 Antimicrobial compositions
05/02/2006US7037450 Production scale method of forming microparticles
05/02/2006CA2401191C A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
05/01/2006CA2498969A1 Acetylcholine-dependent current as a novel ionic target for atrial fibrillation
04/2006
04/27/2006WO2006044573A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
04/27/2006WO2006044077A2 Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
04/27/2006WO2006043710A1 Drug development target protein and target gene, and method of screening
04/27/2006WO2006043701A1 Method of inhibiting phosphorylation of transcriptional factor for gluconeogenesis-associated gene and phosphorylation inhibitor
04/27/2006WO2006043655A1 Medicinal composition for inhalation
04/27/2006WO2006043615A1 Use of immunesuppressant receptor
04/27/2006WO2006043532A1 Therapeutic agent for parkinson's disease
04/27/2006WO2006043510A1 Ester derivative and pharmaceutical use thereof
04/27/2006WO2006043036A2 Treatment of diabetes
04/27/2006WO2006042733A2 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
04/27/2006WO2006021412A3 Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
04/27/2006WO2006020884A3 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
04/27/2006WO2005115359A3 Methods and compositions for the treatment of uveitis
04/27/2006WO2005102296A3 Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
04/27/2006WO2005085421A3 Treatment of spinal conditions
04/27/2006WO2005065712A3 Complexes having adjuvant activity
04/27/2006WO2004021992A3 Delivery of therapeutics to the brain and spinal cord
04/27/2006US20060089404 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
04/27/2006US20060089385 Pharmaceutical compositions
04/27/2006US20060089380 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052)
04/27/2006US20060089349 11beta-hydroxysteroid dehydrogenase type 1 active compounds
04/27/2006US20060089337 Estrogen replacement regimen
04/27/2006US20060089327 Combinations comprising epothilones and anti-metabolites
04/27/2006US20060089326 Immunostimulatory nucleic acid molecules
04/27/2006US20060089320 Modulation of type IIß phosphoinositide phosphate kinase
04/27/2006US20060089313 Methods and compositions for ameliorating the undesirable effects of chemotherapy
04/27/2006US20060089299 Selective treatment of endothelial somatostatin receptors
04/27/2006US20060088913 Mutation associated with epilepsy
04/27/2006US20060088881 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
04/27/2006US20060088880 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
04/27/2006US20060088824 Used in assays to identify PAP-1/WIP-1 interaction inhibitors; West Nile virus (WNV)
04/27/2006US20060088820 Detecting superantigen activity in a biological sample
04/27/2006US20060088603 Compositions and methods for nutrition supplementation
04/27/2006US20060088561 solidifying agent consists of long chain fatty alcohol; carrier is semi-solid at rest and liquefies upon application of shear forces
04/27/2006US20060088545 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therary of diseases associated therewith
04/27/2006US20060088540 Antagonists and methods for inhibiting angiogenesis
04/27/2006US20060088537 Protein involved in cancer
04/27/2006US20060088535 Method for enhancing long-term memory in a subject and uses thereof
04/27/2006US20060088530 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes
04/27/2006US20060088529 Bispecific monoclonal antibodies to IL-12 and IL-18
04/27/2006US20060088511 Cancer therapy sensitizer
04/27/2006US20060088502 Drug for reducing side effects in ribavirin interferon combination therapy
04/27/2006US20060088481 Topical oral dosage forms containing bismuth compounds
04/27/2006DE102004040119A1 Agent, useful for e.g. inactivating infectious prion and decontaminating device, instrument or appliance infected with prion, comprises a nano-particle
04/27/2006CA2584398A1 Ester derivative and pharmaceutical use thereof
04/27/2006CA2584385A1 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
04/27/2006CA2584209A1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
04/26/2006EP1650312A2 Functional assay of high-density lipoprotein
04/26/2006EP1650221A2 Novel compounds
04/26/2006EP1650219A1 Human toll homologues
04/26/2006EP1650188A1 Treatment of tumors with RAR alpha selective retinoid compounds in combination with other anti-tumor agents
04/26/2006EP1649881A1 Drug releasing elastic band and method
04/26/2006EP1649871A1 Retroviral protease inhibitor combinations
04/26/2006EP1649860A1 Pharmaceutical composition for ophthalmic use
04/26/2006EP1649859A1 Pharmaceutical compositions comprising at least one poorly diffusible anticancer drug and a olidodeoxynucleotide immunestimulant
04/26/2006EP1649857A2 New use of glutamate antagonists for the treatment of cancer
04/26/2006EP1649855A1 Medicinal composition
04/26/2006EP1649849A2 Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain.
04/26/2006EP1648910A2 Antisense modulation of stearoyl-coa desaturase expression
04/26/2006EP1648516A2 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
04/26/2006EP1648515A1 Chlorthalidone combinations
04/26/2006EP1648514A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
04/26/2006EP1648493A2 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
04/26/2006EP1648477A2 Injection of bone marrow-derived cells and medium for angiogenesis
04/26/2006EP1648476A1 Mouth and/or throat wash
04/26/2006EP1648474A2 Methods and pharmaceutical compositions for healing wounds
04/26/2006EP1648470A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor
04/26/2006EP1648439A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
04/26/2006EP1648437A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response
04/26/2006EP1648436A1 Ambroxol for treating epilepsy
04/26/2006EP1648435A1 Ambroxol for treating tinnitus
04/26/2006EP1648434A1 Ambroxol for treating chronic nociceptive pains
04/26/2006EP1648428A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
04/26/2006EP1648422A2 Treatment and preventi0n of cardiovascular events
04/26/2006EP1648380A2 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
04/26/2006EP1648376A2 Novel dermatological composition
04/26/2006EP1648364A2 Pharmaceutical compositions for topical application
04/26/2006EP1448281A4 Therapeutic coating for an intravascular implant
04/26/2006EP1421377B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
04/26/2006EP1414467B1 Topical treatment for mastalgia
04/26/2006EP1361894B1 Use of a polyfunctional active substance mixture as an antagonist against harmful substances contained in tobacco smoke acting as a health protecting agent during smoking
04/26/2006EP1313509B1 Treatment of tumors with acetylenes disubstituted with an heteroaromatic group and a substituted thiochromanyl group in combination with other anti-tumor agents
04/26/2006EP1294689B1 Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt
04/26/2006EP1187918B1 Tek antagonists
04/26/2006EP1185666B1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production
04/26/2006EP1066036B1 Agents with serotonin-related activity for the treatment for sleep apnea
04/26/2006EP1009829B1 Adipocyte-specific protein homologs
04/26/2006EP0841949B1 Use of saccharide conjugates
04/26/2006CN1764477A Devices and compositions containing boron and silicon for use in neutron capture therapy
04/26/2006CN1764441A Formulations comprising tolterodine and cocoa powder and use thereof
04/26/2006CN1764440A Formulations comprising an active ingredient and cocoa powder and use thereof